2nd Apr 2012 17:14
Block Listing Six Monthly Return
Information provided on this form must be typed or printed electronically and provided to an RIS.
Date: 2 April 2012
Name of applicant: | Hikma Pharmaceuticals PLC | |||
Name of scheme: | Hikma Pharmaceuticals PLC 2004 Stock Option Plan ("SOP") & Hikma Pharmaceuticals PLC 2005 Long-Term Incentive Plan ("LTIP") | |||
Period of return | From: | 1 October 2011 | To: | 1 April 2012 |
Balance of unallotted securities under scheme(s) from previous return: | SOP: 1,994,300 ordinary shares of 10 pence each LTIP: 0 ordinary shares of 10 pence each | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | SOP: 0 ordinary shares of 10 pence each LTIP: 1,070,000 ordinary shares of 10 pence each | |||
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | SOP: 530,400 ordinary shares of 10 pence each LTIP: 938,400 ordinary shares of 10 pence each | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | SOP: 1,463,900 ordinary shares of 10 pence each LTIP: 131,600 ordinary shares of 10 pence each | |||
Name of contact: | Peter Speirs |
Telephone number of contact: | 0207 399 2772 |
Long Term Incentive Plan ("LTIP") | ||||
Date | Block Listing | Shares Issued | Balance (Headroom) | Notes |
20/12/2011 | 1,070,000 | 1,070,000 | ||
15/03/2012 | 0 | 938,400 | 131,600 | Issued 938,400 to the EBT |
Stock Option Plan ("SOP") | ||||
Date | Block Listing | Shares Issued | Balance (Headroom) | Notes |
17/10/2011 | 0 | 14,000 | 1,980,300 | |
17/10/2011 | 0 | 7,500 | 1,972,800 | |
04/11/2011 | 0 | 1,700 | 1,971,100 | |
21/11/2011 | 0 | 21,600 | 1,949,500 | |
21/12/2011 | 0 | 3,600 | 1,945,900 | |
29/12/2011 | 0 | 460,000 | 1,485,900 | |
29/12/2011 | 0 | 5,100 | 1,480,800 | |
11/01/2012 | 0 | 1,200 | 1,479,600 | |
13/01/2012 | 0 | 3,700 | 1,475,900 | |
19/01/2012 | 0 | 10,000 | 1,465,900 | |
30/03/2012 | 0 | 2,000 | 1,463,900 |
Related Shares:
Hikma Pharmaceuticals